Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular disease, today announced their participation at the ISHLT 44th Annual meeting and Scientific sessions, organized by The International Society for Heart and Lung Transplantation, in Prague, April 10–13, 2024.Cereno Scientific has during the last few months reported positive findings from the ongoing study suggesting a potential positive clinical benefit of drug candidate CS1 in patients with the severe rare disease PAH. Study completion and topline results